Stephen V Liu, MD on Twitter: "The #ESMOVirtualPlenary presented by Dr. @LuisPaz_Ares presents results from EORTC-1416-LCG / ETOP 8-15 / PEARLS / KEYNOTE-091: adjuvant pembrolizumab versus placebo for resected early stage #NSCLC. @
Mary O'Brien, MD @drMaryOBr @royalmarsdenNHS #ASCO22 #OncoTwitter Phase III PEARLS/KEYNOTE-091 Discussion
Pembrolizumab in Early-Stage Non-Small Cell Lung Cancer After Complete Resection
Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to
Stephen V Liu, MD on Twitter: "#ASCO22 While PEARLS did meet its endpoint, we already have atezolizumab approved in this space after IMpower 010. Notes differences between these trials and again -
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
ES/ONCO/1118/0300. - ppt download
PEARLS/KENOTE-091】 完全切除後のぺムブロリズマブは有意に無病生存期間を延長 - キュート先生の『肺癌勉強会』
Adjuvant Immunotherapy in Non–Small Cell Lung Cancer: Who Benefits?
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement In Disease-Free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression 2023 - EORTC
Another Adjuvant Win for Immunotherapy in Early Non-Small Cell Lung Cancer | MedPage Today
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial | AIOM
关于KeyNote-091研究的几点思考及疑惑|人群|患者|研究|错误|阴性|-健康界
KEYNOTE-091研究一举成功，术后辅助NSCLC全人群DFS获益
Treatment benefits and outcome determinants in (neo)adjuvant trials - memoinOncology
PEARLS/KEYNOTE-091: Pembrolizumab vs placebo in early-stage NSCLC
نشرة_أخبار_الأورام | Facebook
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC - YouTube
ES/ONCO/1118/ ppt download
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ on Twitter: "🚨 Adjuvant pembrolizumab for early-stage NSCLC following complete resection: the ph III PEARLS(KEYNOTE-091) by Luis Paz Ares @ETOP_eu @EORTC #LCSM Primary endpoint: DSF in overall population and PDL1
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
癌免疫療法による周術期治療で呼吸器外科の治療体系は変わる(2ページ目)：日経メディカル
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
